Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...
Zacks Investment Research on MSN22h
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With ZealandNovo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback